Glenmark Pharma Appoints Anurag Mantri as Global CFO

Glenmark Pharmaceuticals on Monday, April 7, announced a key leadership change, naming Anurag Mantri as its next Executive Director and Global Chief Financial Officer (CFO). The appointment follows the early retirement of long-serving CFO and Executive Director VS Mani, who will officially step down on May 26, 2025. However, Mani will remain with the company during a transition period to ensure a smooth handover of responsibilities.

In a letter of resignation, Mani cited crossing the age of 60 as a factor in his decision to retire and expressed gratitude for his eight-year tenure. He thanked Glenmark’s Chairman and Managing Director Glenn Saldanha, the board, and his colleagues for their continued support. The company, in return, acknowledged his significant contributions to the business.

Anurag Mantri Brings 30+ Years of Financial Leadership

Anurag Mantri, a seasoned chartered accountant, brings over three decades of experience in finance, global compliance, IPO management, M&A, and corporate strategy. He joins Glenmark from Jindal Stainless Limited, where he served as Executive Director and Group CFO since 2016. Jindal Stainless had disclosed Mantri’s resignation in a regulatory filing on March 21, confirming that he would step down at the close of business hours on April 4, 2025.

Pending board and committee approvals, Mantri is set to take over as Glenmark’s new Executive Director and CFO. His prior roles include senior finance positions at renowned firms such as Larsen & Toubro, HCL Technologies, SRF Limited, Cairn Energy, ACME Group, and Schneider Electric Infrastructure Limited (SEIL). He holds a Bachelor of Commerce degree from the University of Rajasthan.

Stock Performance 

On April 08, 2025, Glenmark Pharmaceuticals share price traded 0.14% higher at ₹1,443.20 at 10:11 AM (IST). Glenmark Pharmaceuticals’ share price reached a 52-week high of ₹1,830.05, and a 52-week low of ₹985.60. As per BSE, the total traded volume for the stock stood at 1,266 shares with a turnover of ₹18.35 lakhs.

According to exchange data, Glenmark Pharmaceuticals shares are trading at a price-to-earnings (P/E) ratio of 6.70x, based on its trailing 12-month earnings per share (EPS) of ₹215.33, and a price-to-book (P/B) ratio of 1.70.

Conclusion 

Glenmark Pharmaceuticals has announced the appointment of Anurag Mantri as its next Executive Director and Global CFO, following the early retirement of VS Mani, effective May 26, 2025. 

Mantri, a chartered accountant with over 30 years of experience, joins from Jindal Stainless Limited. The company praised Mani’s contributions and expressed confidence in Mantri’s leadership, as the transition aims to strengthen governance and support long-term growth amid evolving market dynamics.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.